Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05034536 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05034536 · ClinicalTrials.gov record · last posted 2026-08-24

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

StatusActive, Not Recruiting
PhasePhase 2
Started2022-02-07
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this research is to test the safety and effectiveness of the investigational combination of anti-Programmed Death (PD)-1 antibody therapy with or without LAG-3 inhibition (pembrolizumab or nivolumab+relatlimab) and infliximab in treating metastatic melanoma.

Protocol amendment history 2 changes detected by DataLookout

2026-08-25
Primary completion pushed: 2026-06-30 → 2027-06-30
2026-08-25
Completion pushed: 2027-12-31 → 2028-12-31
Trial Details
NCT Number NCT05034536
Lead Sponsor Massachusetts General Hospital
Collaborators: Massachusetts Institute of Technology
Conditions Metastatic Melanoma
Enrollment 36 participants
Start Date 2022-02-07
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-24